Wrap up: Zenrelia receive EU approval, and other veterinary news

Happy Friday dvm360 readers and happy August! Now that we are in August, that means it is Fetch Kansas City Month. Join the dvm360 team, our amazing faculty, and fellow attendees from August 22-24, 2025, for days of learning, networking, and fun! You can sign up and secure your spot here today, and if you cannot make the conference, check out the dvm360 editorial teams coverage of the event on our dedicated Fetch Kansas City page!

As we eagerly wait for Fetch Kansas City, here is what was popular this week on dvm360.com:

• The American Veterinary Medical Association (AVMA) recently named and honored Michael Blackwell, DVM, MPH, as this year’s AVMA Frederick Douglass Patterson Lifetime Achievement Award winner. Each year this award is given to a veterinary member of the AVMA who had made significant contributors to the profession to promote diversity, equity, and inclusion.
• Elanco Animal Health announced that its ilunocitinib tablets (Zenrelia; Elanco Animal Health) received approval from the European Union and the product will launch immediately into the market before the end of this year’s Q3.
• In this interview with dvm360, Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM), explained to viewers how sodium-glucose cotransporter inhibitors impact polyuria and polydipsia in feline patients with diabetes.
• In his latest installment of the Vet Scene Down Under, Phil Tucak, BSc, BVMS, shares updates on a new consultancy working to turn inclusion into infrastructure, plus tips for pursuing aquatic medicine.
• The FDA issued a warning to pet owners this week to not feed their pets certain lots of Darwin’s Nautral Pet Products after Escherichia coli and Salmonella contamination.
• Did you know that August is Itchy Pet Awareness Month? To kick it off, our episode of The Vet Blast Podcast presented by dvm360, and sponsored by Zoetis, tackles 6 Dastardly Derm Myths. Our host Adam Christman, DVM, MBA, and guest Lissa Capitano DVM, CCFP, dive into each myth and debunk it by sharing personal anecdotes, research, and more!
• And more!